Sign in

CIK 0001061983

  • Large accelerated filer

CYTOKINETICS INC

Sign in to watch
Ticker
CYTK
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
943291317
Phone
+1 650-624-3000
Business address
350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$13,320,469
in 18 filings, $12.5M under 10b5-1 plans

Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-11-17 Malik Fady Ibraham EVP Research & Development Exercise or conversion 10b5-1 +3,500 $7.80 $27K 157,402
2026-11-17 Malik Fady Ibraham EVP Research & Development Sale 10b5-1 −3,300 $51.73 $171K 154,102
2026-11-17 Malik Fady Ibraham EVP Research & Development Sale 10b5-1 −200 $52.59 $11K 153,902
2026-11-17 Malik Fady Ibraham EVP Research & Development Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −3,500 9,386
2026-11-17 Hessekiel Jeffrey Chief Legal & Admin Officer Sale −15,106 $52.62 $795K 92,837
2026-11-16 Blum Robert I President & CEO Exercise or conversion 10b5-1 +7,500 $10.60 $80K 286,044
2026-11-16 Blum Robert I President & CEO Sale 10b5-1 −5,077 $53.22 $270K 280,967
2026-11-16 Blum Robert I President & CEO Sale 10b5-1 −2,223 $54.08 $120K 278,744
2026-11-16 Blum Robert I President & CEO Sale 10b5-1 −200 $55.21 $11K 278,544
2026-11-16 Blum Robert I President & CEO Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −7,500 126,745
2026-11-09 PARSHALL B LYNNE Director Sale 10b5-1 −2,445 $54.17 $132K 8,339
2026-11-09 PARSHALL B LYNNE Director Sale 10b5-1 −2,555 $55.26 $141K 5,784
2026-11-03 Malik Fady Ibraham EVP Research & Development Exercise or conversion 10b5-1 +3,500 $7.80 $27K 157,402
2026-11-03 Malik Fady Ibraham EVP Research & Development Sale 10b5-1 −3,500 $62.93 $220K 153,902
2026-11-03 Malik Fady Ibraham EVP Research & Development Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −3,500 12,886
2026-11-02 Blum Robert I President & CEO Exercise or conversion 10b5-1 +7,500 $10.60 $80K 286,044
2026-11-02 Blum Robert I President & CEO Sale 10b5-1 −7,500 $62.81 $471K 278,544
2026-11-02 Blum Robert I President & CEO Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −7,500 134,245
2026-10-20 Malik Fady Ibraham EVP Research & Development Exercise or conversion 10b5-1 +3,500 $7.80 $27K 157,402
2026-10-20 Malik Fady Ibraham EVP Research & Development Sale 10b5-1 −3,500 $64.01 $224K 153,902

Page 1 of 45 · 885 trades